InvestLog
WHWK Whitehawk Therapeutics Inc logo

WHWK Whitehawk Therapeutics Inc

Healthcare
$4.49+4.42%ClosedMarket Cap: $222.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.68

P/S

0.00

EV/EBITDA

-1.58

DCF Value

$-4.61

FCF Yield

-44.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-79.6%

ROA

-91.0%

ROIC

-105.6%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-22.2M$—
Q4 null$0.00$-23.3M$—
FY null$7.1M$-20.6M$—
Q3 null$0.00$-17.7M$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$7.00

Target (Median)

$7.00

Target Range

$7.00 - $7.00

1 Strong Buy2 Buy3 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Lennon David Jamesdirector, officer: CHIEF EXECUTIVE OFFICER
SellMon May 18
Giacobello Scott M.officer: CHIEF FINANCIAL OFFICER
SellMon May 18
Dugan Margaretofficer: Chief Medical Officer
SellMon May 18
Castelein Caleydirector
SellMon May 18
Castelein Caleydirector
SellMon May 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.71

Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.

Peers

ATOS logoATOSCLNN logoCLNNCNTX logoCNTXIMMX logoIMMXMGNX logoMGNXONCY logoONCYOVID logoOVIDPLRX logoPLRXTVGN logoTVGNZNTL logoZNTL